Association for Molecular Pathology Annual Meeting

Long-Range PCR Meets Long-Read Sequencing: An Assay for 11 Hard-to-Decipher, High-Frequency Carrier Screening Associated Genes

In this workshop, Dr. Wadsworth of Stanford University will discuss the design and performance of the AmplideX^® Carrier Plus Kit, combining Amplidex chemistry with the Oxford Nanopore^® platform to identify the most challenging genetic alterations like CNVs, large inversions, and pseudogenes using a consolidated workflow.

Speaker:

Paul A. Wadsworth, MD, PhD
Resident Physician, Pathology
Stanford University

Wednesday, November 20,
12:00-12:50 PM PST
Room 114/115

ESR1 & Beyond: Leveraging Exosomes for Highly-Sensitive Variant Detection on qPCR

In this workshop, we will showcase the design and performance of the QuantideX^® qPCR ESR1 exoMutation Kit combined with the ExoLution Plus cfDNA/exosomal RNA Isolation Kit to deliver sensitivity of ≤0.1% for 11 ESR1 mutations located in the ligand-binding domain, utilizing the power of cfDNA and exosomal RNA isolated from exosomes to deliver best in class performance.

Speaker:

Brian Haynes, PhD
Chief Scientific Officer,
Bio-Techne Diagnostics Division

Wednesday, November 20,
3:00-3:50 PM PST
Room 212/213

Oxford Nanopore: Advancing Human Genetics & Cancer Research

Learn how sequencing solutions from Oxford Nanopore Technologies are transforming molecular pathology. Hear about the latest developments in nanopore sequencing which provide a comprehensive view of both conventionally sequenced single nucleotide variants and small indels, and the detection of structural, repetitive, copy number, and methylation variants ― all in a single sequencing run. With its ability to read any length of DNA or RNA, from short to ultra-long, come and learn how nanopore technology empowers you to answer the bigger and bolder research questions you have always wanted to ask.

Speaker:

Anne-Sophie Lebre
Professor of Human Genetics & Clinical Molecular Geneticist,
Reims Medical School & University Hospital

Wednesday, November 20,
2:00-2:50 PM PST
Room 109

Fireside Chat: LDT Compliance in an Uncertain Environment

With so much uncertainty around the FDA’s LDT Rule, it is challenging for laboratory leaders to make firm plans for how to achieve compliance. This session will consider three different tactical approaches for stage I of the rule: a) labs actively preparing for compliance; b) labs preparing, but cautiously using resources; and c) labs that are deferring preparation. No matter where your lab is on the spectrum, please join this interactive session as we discuss aspects of each approach and the practicalities of adjusting to the new regulatory landscape.

Discussion Leader:

Jordan Laser, MD
Senior Director,
Clinical & Medical Affairs

Wednesday, November 20,
5:15-6:15 PM PST
Room 211

Streamlining carrier screening insights, even for the most challenging genes.

Asuragen is leveraging its gold-standard PCR technology with Oxford Nanopore’s long-read DNA sequencing capabilities to develop the first sequencing system to resolve the most challenging, high-prevalence carrier genes in a single, unified workstream that today requires multiple other methods.

The QuantideX qPCR ESR1 exoMutation Kit is paired with the ExoLution Plus cfDNA + exoRNA Isolation Kit, leveraging proprietary chemistries to co-isolate cfDNA + exoRNA in a single workflow. ExoLution Plus includes all necessary reagents and consumables for high-quality, multi-analyte isolation to power downstream mutation testing.